Madrigal Pharmaceuticals (MDGL) EBITDA Margin (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly EBITDA Margin of 15.46% for Q2 2026, up 672.0% year-over-year from 2.0% in Q2 2025, and up 48.09% quarter-over-quarter from 29.78% in Q1 2026.
Madrigal Pharmaceuticals (MDGL) EBITDA Margin (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported EBITDA Margin for 6 consecutive years, with 15.46% the latest figure, recorded in Q2 2026.
- In Q2 2026, EBITDA Margin rose 672.0% year-over-year to 15.46%; the TTM figure through Jun 2026 stood at 25.13% (up 3497.0% YoY), while the FY2025 annual figure was 31.31%, up 24508.0% from the prior year.
- EBITDA Margin climbed to 15.46% in Q2 2026 per MDGL's latest filing, from 29.78% in the prior quarter.
- Across five years, EBITDA Margin topped out at 15.46% in Q2 2026 and bottomed at 1110.38% in Q2 2024.
- Historically, EBITDA Margin has averaged 171.75% across 3 years, with a median of 39.68% in 2025.
- Annual changes were most pronounced in 2025 — EBITDA Margin surged 108820 bps — and 2026, when it soared 672 bps.
- Madrigal Pharmaceuticals' EBITDA Margin stood at 64.84% in 2024, then surged by 71 bps to 18.56% in 2025, then advanced by 17 bps to 15.46% in 2026.
- Business Quant data shows MDGL's EBITDA Margin at 15.46% in Q2 2026, 29.78% in Q1 2026, and 18.56% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | -15.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.46% |
| Mar 31, 2026 | -29.78% |
| Dec 31, 2025 | -18.56% |
| Sep 30, 2025 | -39.68% |
| Jun 30, 2025 | -22.18% |
| Mar 31, 2025 | -57.79% |
| Dec 31, 2024 | -64.84% |
| Sep 30, 2024 | -187.06% |
| Jun 30, 2024 | -1,110.38% |
| Sep 30, 2012 | -29,413.61% |
| Jun 30, 2012 | -19,523.13% |
| Mar 31, 2012 | -9,908.16% |
| Dec 31, 2011 | -8,461.98% |
| Sep 30, 2011 | -734.25% |
| Jun 30, 2011 | -5,691.47% |
| Mar 31, 2011 | -959.41% |
| Dec 31, 2010 | -207.21% |
| Sep 30, 2010 | -302.42% |
| Jun 30, 2010 | -269.17% |